<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Neuropsychopharmacology</journal-id>
<journal-id journal-id-type="iso-abbrev">Neuropsychopharmacology</journal-id>
<journal-title-group>
<journal-title>Neuropsychopharmacology</journal-title>
</journal-title-group>
<issn pub-type="ppub">0893-133X</issn>
<issn pub-type="epub">1740-634X</issn>
<publisher>
<publisher-name>Nature Publishing Group</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">26567514</article-id>
<article-id pub-id-type="pmc">4869042</article-id>
<article-id pub-id-type="pii">npp2015341</article-id>
<article-id pub-id-type="doi">10.1038/npp.2015.341</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Selective Mitochondrial Targeting Exerts Anxiolytic Effects <italic>In Vivo</italic></article-title>
<alt-title alt-title-type="running">Anxiolytic effects of mitochondrial targeting</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Nussbaumer</surname>
<given-names>Markus</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Asara</surname>
<given-names>John M</given-names>
</name>
<xref ref-type="aff" rid="aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Teplytska</surname>
<given-names>Larysa</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Murphy</surname>
<given-names>Michael P</given-names>
</name>
<xref ref-type="aff" rid="aff3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Logan</surname>
<given-names>Angela</given-names>
</name>
<xref ref-type="aff" rid="aff3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Turck</surname>
<given-names>Christoph W</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Filiou</surname>
<given-names>Michaela D</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
<xref ref-type="corresp" rid="caf1">*</xref>
</contrib>
<aff id="aff1"><label>1</label><institution>Max Planck Institute of Psychiatry</institution>, Munich, <country>Germany</country></aff>
<aff id="aff2"><label>2</label><institution>Division of Signal Transduction, Beth Israel Deaconess Medical Center, Department of Medicine, Harvard Medical School</institution>, Boston, <country>MA</country>, <country>USA</country></aff>
<aff id="aff3"><label>3</label><institution>MRC-Mitochondrial Biology Unit</institution>, Cambridge, <country>UK</country></aff>
</contrib-group>
<author-notes>
<corresp id="caf1"><label>*</label><institution>Proteomics and Biomarkers, Max Planck Institute of Psychiatry</institution>, Kraepelinstr. 2, Munich 80804, <country>Germany</country>, Tel: +49 89 30622 506, Fax: +49 89 30622 200, E-mail: <email>mfiliou@psych.mpg.de</email></corresp>
</author-notes>
<pub-date pub-type="ppub">
<month>06</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="epreprint">
<day>16</day>
<month>11</month>
<year>2015</year>
</pub-date>
<pub-date pub-type="epub">
<day>16</day>
<month>12</month>
<year>2015</year>
</pub-date>
<volume>41</volume>
<issue>7</issue>
<fpage>1751</fpage>
<lpage>1758</lpage>
<history>
<date date-type="received">
<day>26</day>
<month>05</month>
<year>2015</year>
</date>
<date date-type="rev-recd">
<day>22</day>
<month>10</month>
<year>2015</year>
</date>
<date date-type="accepted">
<day>08</day>
<month>11</month>
<year>2015</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright Â© 2016 American College of Neuropsychopharmacology</copyright-statement>
<copyright-year>2016</copyright-year>
<copyright-holder>American College of Neuropsychopharmacology</copyright-holder>
</permissions>
<abstract>
<p>Current treatment strategies for anxiety disorders are predominantly symptom-based. However, a third of anxiety patients remain unresponsive to anxiolytics highlighting the need for more effective, mechanism-based therapeutic approaches. We have previously compared high <italic>vs</italic> low anxiety mice and identified changes in mitochondrial pathways, including oxidative phosphorylation and oxidative stress. In this work, we show that selective pharmacological targeting of these mitochondrial pathways exerts anxiolytic effects <italic>in vivo</italic>. We treated high anxiety-related behavior (HAB) mice with MitoQ, an antioxidant that selectively targets mitochondria. MitoQ administration resulted in decreased anxiety-related behavior in HAB mice. This anxiolytic effect was specific for high anxiety as MitoQ treatment did not affect the anxiety phenotype of C57BL/6N and DBA/2J mouse strains. We furthermore investigated the molecular underpinnings of the MitoQ-driven anxiolytic effect and found that MitoQ treatment alters the brain metabolome and that the response to MitoQ treatment is characterized by distinct molecular signatures. These results indicate that a mechanism-driven approach based on selective mitochondrial targeting has the potential to attenuate the high anxiety phenotype <italic>in vivo,</italic> thus paving the way for translational implementation as long-term MitoQ administration is well-tolerated with no reported side effects in mice and humans.</p>
</abstract>
</article-meta>
</front>
</article>
</pmc-articleset>